ADx NeuroSciences was founded in 2011 by pioneers in biomarker development and Alzheimer’s disease research. We combine more than 45 years of knowledge and experience, and have built an impressive track record developing superior, highly performant and unique diagnostic biomarkers.
Chief Executive Officer and founder
Koen Dewaele, MSc Biology, has more than 35 years of experience in the in vitro diagnostic industry. He held several positions during his career but could excel most when leading the Alzheimer program, first at Innogenetics before 2010 and later as co-founder and CEO of ADx NeuroSciences. He has a good understanding of both the market and the science which helps to define the best strategy forward for success. Besides, he is a strong people manager. In 2022 he led the successful acquisition of ADx NeuroSciences by Fujirebio. His next ambition is to create together with Fujirebio a worldwide market leadership position in the development and supply of novel diagnostic biomarkers for neurodegenerative diseases.
KDIV Consult bvba is represented by its permanent representative Koen Dewaele
Chief Scientific Officer and founder
Eugeen Vanmechelen received his PhD in Molecular Biology at the University of Ghent. He joined Innogenetics in 1987 where he pioneered the first biomarkers in cerebrospinal fluid for Alzheimer’s disease together with Kaj Blennow (University of Gothenburg). His research on the first phospho-tau assays was described in 1990 and is the foundation for some of the current blood-based biomarkers in Alzheimer’s disease. All of this work was published in peer-reviewed journals with a current H-index of 72. He was also inventor (and co-inventor) of more than 10 granted patents. Several national and pharma project proposals were approved to expedite the development of new biomarkers and he is still involved in several international projects (e.g. EU Miriade project). In the Alzheimer’s ecosystem he has been invited to various national and international grant committees. With a passion for research, he likes to guide new scientists and interns to further gain new scientific insights in brain diseases and accelerate the translation to improved diagnosis in the future.
Key4AD Consult bvba is represented by its permanent representative Eugeen Vanmechelen
Ann De Vos
Director Business Development
Ann De Vos (PhD in Biology – background in sales (Merck Millipore)), joined ADx at the start of the company as a scientist. She designed immunoassays for, and coordinated studies on, several biomarkers like neurogranin, which resulted in a.o. a patent of which she is co-inventor. As she is a great organizer and entrepreneur, she took on additional responsibilities as the company grew. As examples, ADx’ pharma program was established and a biobank certified by the Belgian government was set up within ADx. However, her passion has always been getting research insights translated into something useful for the field so her biggest commitment always remained business development. Now as ADx’ Business Development Director, she is ever enthusiastic to find the right tools for the right partner at the right time.
Director Biomarker Development
Erik Stoops holds a Master Engineering degree in Biochemistry from the University of Gent, Belgium and has more than 25 years of experience in the diagnostic industry and has been working on neurodegenerative disorder biomarkers since 2012. Erik has a track record of successfully building and growing innovation-driven diagnostic based companies (Innogenetics, BioMARIC and ADx NeuroSciences). At ADx he led efforts towards development and successful establishment of various body fluid biomarker tests. In his current position he leads the biomarker development programs to support clinical use of the biomarkers and in therapeutic development programs and is member of the core strategic team of the company. In addition he is involved in precompetitive consortia and working groups, was co-PI and PI in grants and contributed to peer reviewed publications on biomarker development, validation and integration into the neurodegeneration field.